18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers

Nuclear Medicine Communications

Volumn 32, Issue 3, 2011, Pages 168-176

  Withofs, Nadia ^a   Grayet, Benjamin ^b   Tancredi, Tino ^b   Rorive, Andrée ^c   Mella, Christine ^d   Giacomelli, Fabrice ^d   Mievis, Frédéric ^d   Aerts, Joël ^d   Waltregny, David ^a   Jerusalem, Guy ^c   Hustinx, Roland ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Department of Medical Imaging ^*  (Belgium)

^c Division of Medical Oncology   (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

18F fluoride; bone metastases; breast cancer; PET computed tomography; prostate cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUORINE 18; FLUOROURACIL; HORMONE ANTAGONIST; MEDRONATE TECHNETIUM TC 99M; PACLITAXEL; ZOLEDRONIC ACID; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE POSITIVE RESULT; FEMALE; GOLD STANDARD; HIGH RISK PATIENT; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BONE TUMOR; BREAST TUMOR; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; METASTASIS; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STANDARD;

BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79451471348     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283412ef5     Document Type: Article

References (25)

1. Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006; 24:5091-5097.
2. Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. Localized prostate cancer. N Engl J Med 2007; 357:2696-2705.
3. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22:2942-2953.
4. Ghanem N, Uhl M, Brink I, Schafer O, Kelly T, Moser E, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CTand PET/CTfor the detection of metastases of bone. Eur J Radiol 2005; 55:41-55.
5. Costelloe CM, Rohren EM, Madewell JE, Hamaoka T, Theriault RL, Yu TK, et al. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 2009; 10:606-614.
6. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006; 107:2545-2551.
7. Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 2008; 26:712-720.
8. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004; 34:274-292.
9. Beheshti M, Langsteger W, Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med 2009; 39:396-407.
10. 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 2008; 35:1766-1774.
11. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med 1962; 3:332-334.
12. 99mTc-methylene diphosphonate. Semin Nucl Med 2001; 31:28-49.
13. 18F-fluoride: applying newtechnology to an old tracer. J Nucl Med 2008; 49:68-78.
14. 18F- fluoride measured with positron emission tomography in correlation with CT. Skeletal Radiol 1998; 27:72-76.
15. Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kuhn T, Kreienberg R, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999; 17:2381-2389.
16. 18F PET. J Nucl Med 1999; 40:1623-1629.
17. Schirrmeister H, Glatting G, Hetzel J, Nussle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001; 42:1800-1804.
18. Hetzel M, Arslandemir C, Konig HH, Buck AK, Nussle K, Glatting G, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res 2003; 18:2206-2214.
19. 18F-fluoride PET/CT. J Nucl Med 2004; 45:272-278.
20. 18F-fluoride PET/CT. J Nucl Med 2006; 47:287-297.
21. Ndlovu X, George R, Ellmann A, Warwick J. Should SPECT-CT replace SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies? Nucl Med Commun 2010; 31:659-665.
22. Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology 1998; 209:253-258.
23. 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med2009; 50:501-505.
24. Kruger S, BuckAK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, et al. Detection of bone metastases in patients with lung cancer: (99m)Tc-MDP planar bone scintigraphy, (18)F-fluoride PETor (18)F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009; 36:1807-1812.
25. Nakamoto Y, Cohade C,Tatsumi M, Hammoud D, Wahl RL. CTappearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology2005; 237:627-634.